Befotertinib mesylate (D-0316 mesylate) is third-generation tyrosine kinase inhibitor (TKI) of EGFR . It can be used for the research of EGFR T790M-positive non-small cell lung cancer (NSCLC).
More Information Supplier PageBefotertinib mesylate (D-0316 mesylate) is third-generation tyrosine kinase inhibitor (TKI) of EGFR . It can be used for the research of EGFR T790M-positive non-small cell lung cancer (NSCLC).
More Information Supplier PageSLF1081851 hydrochloride is a potential inhibitor of Spns2 that blocks S1P release with an IC50 of 1.93 μM. It can be developed as a probe for studying Spns2 biology and immune modulation.
More Information Supplier PageSLF1081851 hydrochloride is a potential inhibitor of Spns2 that blocks S1P release with an IC50 of 1.93 μM. It can be developed as a probe for studying Spns2 biology and immune modulation.
More Information Supplier PageSLF1081851 hydrochloride is a potential inhibitor of Spns2 that blocks S1P release with an IC50 of 1.93 μM. It can be developed as a probe for studying Spns2 biology and immune modulation.
More Information Supplier PageSLF1081851 hydrochloride is a potential inhibitor of Spns2 that blocks S1P release with an IC50 of 1.93 μM. It can be developed as a probe for studying Spns2 biology and immune modulation.
More Information Supplier PageDDO-2728 is a selective pyrazolopyrimidine-based inhibitor of ALKBH5 with an IC50 of 2.97 μM. It increases the levels of N6-methyladenosine (m6A) modifications in acute myeloid leukemia (AML) cells and exhibits antiproliferative activity in these cells. It also demonstrates anti-tumor efficacy in the MV4−11 xenograft model.
More Information Supplier PageDDO-2728 is a selective pyrazolopyrimidine-based inhibitor of ALKBH5 with an IC50 of 2.97 μM. It increases the levels of N6-methyladenosine (m6A) modifications in acute myeloid leukemia (AML) cells and exhibits antiproliferative activity in these cells. It also demonstrates anti-tumor efficacy in the MV4−11 xenograft model.
More Information Supplier PageDDO-2728 is a selective pyrazolopyrimidine-based inhibitor of ALKBH5 with an IC50 of 2.97 μM. It increases the levels of N6-methyladenosine (m6A) modifications in acute myeloid leukemia (AML) cells and exhibits antiproliferative activity in these cells. It also demonstrates anti-tumor efficacy in the MV4−11 xenograft model.
More Information Supplier PageDDO-2728 is a selective pyrazolopyrimidine-based inhibitor of ALKBH5 with an IC50 of 2.97 μM. It increases the levels of N6-methyladenosine (m6A) modifications in acute myeloid leukemia (AML) cells and exhibits antiproliferative activity in these cells. It also demonstrates anti-tumor efficacy in the MV4−11 xenograft model.
More Information Supplier Page
